Actively Recruiting
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Led by University Hospital, Strasbourg, France · Updated on 2025-08-08
100
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating new ways to prevent and treat BK virus (BKV) infection, which negatively affects transplant recipients. Since there are currently no specific antiviral treatments for BKV, this study aims to explore novel therapeutic approaches based on monoclonal antibodies. The study is observational and seeks to better understand these antibodies' ability to neutralize different BKV genotypes. The study will focus on isolating monoclonal antibodies and evaluating their capacity to neutralize all three known BKV genotypes over a period of five years. No specific treatments or interventions are being administered as part of this observational study. Instead, the research aims to collect relevant data on these antibodies and their potential role in combating BKV infection. Participants will be adults who have tested positive for BK virus infection and agree to participate in research. The study involves monitoring and assessing the neutralizing ability of the isolated monoclonal antibodies against BKV. Researchers will measure this primary outcome over a five-year follow-up period. There are no treatment visits or drug administrations, but ongoing observation and data collection will take place during the study timeframe, which lasts until December 2025.
CONDITIONS
Brief Title
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BK positive
- Adult
- Agree to participate in research
You will not qualify if you...
- Under guardianship
- Under curatorship
- Opposed to research
- Deprived of liberty
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are monitored over time to assess the ability of isolated monoclonal antibodies to neutralize BK virus genotypes.
Periodic visits over 5 years
Trial Site Locations
Total: 1 location
1
Service de Virologie - CHU Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
A
Anne-Sophie U GEY
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here